Programs & ResourcesBack

Programs & ResourcesBack

Programs and Resources for You to Help Your Patients Fight Periodontal Disease

The following programs and resources are designed to give dental healthcare professionals of all practice levels the information they need to help patients fight periodontal disease.


ARESTIN® Rx Access — ARESTIN® Rx Access is a convenient way to find out if patients’ medical insurance prescription benefits cover treatment with ARESTIN®.


ARESTIN® Student Access — A program sponsored by OraPharma, Inc. that gives dental students clinical information and hands-on training in comprehensive periodontal treatment including ARESTIN® + scaling and root planing (SRP).


Webinars & Training Videos — Watch and learn more about the benefits of ARESTIN® for both dental healthcare professionals and patients.


Getting Started With ARESTIN®  — The information practices need to start using ARESTIN®.


Forms & Brochures — Download and print practice resources.

Register to become a member of MyArestin™. 

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13